Hyqvia

Human normal immunoglobulin and recombinant hyaluronidase, the active ingredients in Hyqvia, are an immunoglobulin (IgG) and hyaluronidase enzyme presented as a solution for subcutaneous infusion use. They provide passive immunity for patients with primary immunodeficiency diseases such as common variable immunodeficiency, X‑linked agammaglobulinemia, and severe combined immunodeficiency.

GNH USA supplies Hyqvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products throughout the globe.

Hyqvia is used to replace deficient antibodies in primary immunodeficiency disorders, helping to reduce infection risk.

- Common Variable Immunodeficiency (CVID): restores IgG levels to decrease frequency and severity of infections. - X‑linked Agammaglobulinemia (XLA): provides necessary immunoglobulin to prevent bacterial infections. - Severe Combined Immunodeficiency (SCID): supplies passive immunity as part of long‑term management.

Hyqvia may be associated with a range of adverse reactions, most of which are mild and related to the infusion process.

Common Side Effects: - Injection site pain or swelling - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Thrombotic events such as deep vein thrombosis - Renal impairment or acute kidney injury

When using Hyqvia, certain precautions should be observed to ensure patient safety and product integrity.

- Screen for IgA deficiency: patients with anti‑IgA antibodies may have increased risk of severe reactions. - Monitor renal function: adjust therapy in patients with existing kidney disease. - Assess thrombotic risk: avoid rapid infusion rates in individuals with a history of clotting disorders. - Evaluate for uncontrolled asthma or severe pulmonary disease before administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hyqvia can interact with other medicines; awareness of these interactions helps to minimize adverse outcomes.

Major Interactions (Avoid): - Live vaccines: may cause reduced efficacy or heightened infection risk. - Concurrent use of other immunoglobulin products: may lead to immunoglobulin overload. - High‑dose immunosuppressants: can diminish therapeutic benefit of Hyqvia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may increase risk of renal impairment during therapy. - Diuretics: may affect fluid balance and increase infusion‑related discomfort. - Anticoagulants: monitor for bleeding if infusion rate is rapid.